U.S. Markets close in 4 hrs 51 mins

U.S. FDA panel split over approval of Durect's non-opioid painkiller

Jan 16 (Reuters) - Independent experts on an FDA advisory panel on Thursday were split over the approval of Durect Corp's experimental non-opioid painkiller to manage post-surgical pain.

Six members voted in favor, while six others voted against the drug Posimir, a reformulated version of the anesthetic bupivacaine that aims to provide pain relief for up to three days after surgery.

The panel's recommendation plays an influential role in the FDA's final decision. (Reporting by Trisha Roy and Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur)